Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug eluting stents: initial experiences.

E Grube1, U Gerckens, R Müller

  • 1Heart-Center Siegburg Ringstrasse 49 53721 Siegburg, Germany. GrubeE@aol.com

Zeitschrift Fur Kardiologie
|March 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of Pre- and Intensified Postprocedural Physiotherapy in Patients with Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Study (the 4P-TAVR Study).

Journal of interventional cardiology·2021
Same author

Innovations and novel technologies in TAVI. Second generation transcatheter heart valves.

Minerva cardioangiologica·2013
Same author

Impact of coronary artery disease on in-hospital mortality in patients with aortic valve disease. Results from the German ALKK registry.

Herz·2013
Same author

First-In-Man application of a miniature self-contained intracoronary magnetic resonance probe. A multi-centre safety and feasibility trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009
Same author

First experience with the Impella Recover(R) LP 2.5 micro axial pump in patients with cardiogenic shock or undergoing high-risk revascularisation.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009
Same author

Advances in percutaneous treatment for adult valvular heart disease.

Internal medicine journal·2009
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[On pathogenesis of coronary heart disease].

Zeitschrift fur Kardiologie·2016
Same journal

An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis.

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Reconstructive surgery of the aortic root].

Zeitschrift fur Kardiologie·2016
See all related articles

Drug-eluting stents effectively inhibit in-stent restenosis by delivering antiproliferative agents like Paclitaxel and Sirolimus. While showing significant reduction in restenosis, further evaluation of drug toxicity and optimal dosage is needed for coronary lesion treatment.

Area of Science:

  • Interventional Cardiology
  • Biomaterials Science
  • Pharmacology

Background:

  • Drug-eluting stents (DES) represent a novel approach to inhibit in-stent restenosis.
  • They combine biological and mechanical solutions for treating coronary lesions.
  • Several agents, including Paclitaxel and Sirolimus, are under investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of drug-eluting stents in preventing in-stent restenosis.
  • To assess the performance of different antiproliferative agents delivered via stents.
  • To summarize current clinical experience with drug-coated stents.

Main Methods:

  • Review of published and ongoing clinical trials (e.g., SCORE, TAXUS, RAVEL, SIRIUS).
  • Analysis of drug release kinetics, dosage, safety, and clinical benefit.

Related Experiment Videos

  • Comparison of restenosis rates and major adverse cardiac events (MACE) between DES and control groups.

    • Main Results:

    • Paclitaxel-eluting stents demonstrated significant reduction in restenosis (e.g., 83% in SCORE trial) but with associated risks like thrombosis.
    • Sirolimus-eluting stents showed beneficial reduction in renarrowing without adverse effects in RAVEL and SIRIUS trials.
    • Early studies indicate a promising reduction in intimal proliferation and restenosis.

    Conclusions:

    • Drug-eluting stents are a promising strategy for interventional treatment of coronary lesions.
    • Sirolimus-eluting stents have shown positive results with no adverse effects in initial trials.
    • Further research is required on drug toxicity, optimal dosage, and endothelial healing.